Anti-angiogenic agent, platform planned for human trialFindings from preclinical studies show that a novel intravitreal depot of an anti-angiogenic drug releases the medication over a period of at least 6 months, is well-tolerated, and prevents VEGF-induced retinal vascular leakage.
2017 Research Scholar Honoree Program
2017 Research Scholar Honoree Program
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
HHS, drugmaker partner on Ebola drugThe U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals in Tarrytown, New York, are partnering to develop a novel Ebola virus treatment.
Newly approved PCSK9 inhibitor comes with hefty priceWhile the FDA’s approval of alirocumab (Praluent injection) for high cholesterol is an important new treatment for patients with cardiovascular disease, health plan executives and others are worried about the drug’s price tag.
IL-6 inhibitor shows positive clinical benefit in RA patientsSarilumab may be an effective option for patients with moderately-to-severely active rheumatoid arthritis (RA) according to topline results from a new study.
Battle of the cholesterol drugs expectedThis summer, Amgen and Regeneron Pharmaceuticals/ Sanofi will battle it out in the competitive cholesterol market. Repatha and Praluent, respectively, are expected to be approved by the FDA this summer.
FDA expanded approval of aflibercept injection to treat diabetic retinopathyFDA has expanded the approval of aflibercept (Eylea, Regeneron) injection to treat diabetic retinopathy in patients with macular edema.
DME study: Aflibercept injection shows greater gains in visual acuity than alternative anti-VEGF therapiesIn patients with moderate or worse vision loss at baseline, those treated with aflibercept (Eylea, Regeneron) Injection gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative anti-VEGF therapies, according to a study published in the New England Journal of Medicine.
Investigational PCSK9 inhibitor lowers LDL-C, may reduce cardiovascular eventsAlirocumab (Praluent), a PCSK9 inhibitor, reduced low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy, according to a study published online in the New England Journal of Medicine.